U.S. markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.50%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.36%)
     
  • BTC-USD

    48,772.41
    -6,120.57 (-11.15%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

India's Biological E To Make Johnson & Johnson's COVID-19 Shots: Reuters

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Johnson and Johnson (NYSE: JNJ) has joined hands with India-based Biological E Limited to manufacture its COVID-19 vaccine, alongside Biological E's COVID-19 vaccine candidate, which could boost the country's overall supplies amid a shortage.

  • "The infrastructure and plants are completely separate for both the products and we will be producing both independent of each other," said Mahima Datla, Managing Director & CEO of Biological E, in a text message, declining to give any timeline or other details.

  • According to Reuters, Biological E. was looking to contract-manufacture about 600 million doses of the J&J vaccine annually.

  • In the list of likely vaccine output for 2021 released last week, the Indian government did not factor in any production of the J&J COVID-19 Vaccine.

  • Reuters notes J&J has confirmed it was working with Biological E. on manufacturing its vaccine.

  • "We believe Biological E. will be an important part of our global COVID-19 vaccine supply network, where multiple manufacturing sites are involved in the production of our vaccine across different facilities, sometimes in different countries and continents, before the vaccine can be distributed," a J&J India spokesperson said.

  • J&J said last month it had sought permission to conduct a local clinical trial in India for its single-dose vaccine.

  • Biological E., based in the southern Indian city of Hyderabad, also plans to produce 75 million to 80 million doses of its vaccine a month from August. The drug has been developed with Baylor College of Medicine in Houston and Dynavax Technologies Corporation (NASDAQ: DVAX).

  • Price Action: JNJ shares closed at $170.45 on Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.